







Synthesis and Investigation the Biological Activity of Some New Alkenes Based on Thiazolidin-4-One Compounds

Israa Abd Al Hassan Hamdan^{1,2,*}   and J. H. Tomma²  

¹Department of Biology, College of Education For Pure Science, Al- Muthanna University, Muthanna, Iraq.

²Department of Chemistry, College of Education For Pure Science (Ibn Al-Haitham), University of Baghdad, Baghdad, Iraq.

*Corresponding Author.

Received: 8 October 2023

Accepted: 11 December 2023

Published: 20 October 2024

doi.org/10.30526/37.4.3779

Abstract

This work has been done to prepare a series of new alkene compounds derived from 4-thiazolidinones by substituting different aldehydes, P-acetamido-phenol, and 2-mercapto-benzoimidazole, which were used as starting materials to form ester [I]_{a,b} and then make hydrazides [II]_{a,b}, which were used to prepare 1, 3, and 4-oxadiazoles [III]_{a,b}, which were then used for prepared Schiff bases [IV]_{a-f}. The next step was the synthesis of 4-thiazolidinone derivatives [V]_{a-f} from Schiff bases. The final step was the synthesis of alkenes [VII]_{a-f}, the prepared derivatives were identified with spectral methods (FT-IR, ¹H-NMR, mass, and CHNS). The antibacterial activity of the prepared derivatives was evaluated against four types of bacteria, positive gram (*Staphylococcus aureus* and *Enterococcus faecalis*.) and negative gram (*E. coli* and *Pseudomonas aerugionsa*). The final compounds gave high to moderate efficacy against *Enterococcus faecalis* bacteria, molecular modeling study against one of the SARS human coronavirus proteins was tested for synthesis compounds. Compound [VII]_c had a high bonding strength with the target protein, wherever it was -8.08 Kcal/mole followed by the compound [VII]_a. in the bonding strength energy, which was -7.65Kcal/mole.

Keywords: Alkenes, antibacterial activity, molecular docking, Schiff bases, thiazolidin-4-ones.

1. Introduction

Heterocyclic compounds (i.e., containing heterogeneous atoms such as nitrogen, sulfur, and oxygen) are important in various fields of science such as medicine, industry, agriculture, and pharmaceuticals [1–3]. There is much interest in these compounds and their new derivatives. 1,2,3-Thiosolidinones, a class of heterocyclic compounds with five members, hold significant biological and medical importance due to their incorporation of elements such as oxygen, nitrogen, and sulfur. In addition to the carbonyl group on C5, S at location 1, N at location 3, and CH₂ at location 2, 4, and 5 are found with ring structure, which increase their effectiveness against many microorganisms as well as diseases [4,5], like the nucleus of 4-thiazolidine is included in the composition of diabetes medications [6], it also expands the



targets of its work to include antiviral, antifungal, anti-parasitic, and anti-cancer [7], anti-tuberculosis [8,9], antibacterial [10], and anticonvulsant activity [11]. This work prepared new compounds of alkenes containing a 4-thiazolidine nucleus, evaluated their biological activity, and conducted molecular modeling.

2. Materials and Methods

2.1 Instrumental

All chemicals were employed without purification; a specific company supplied them. The melting point was measured by using Gallen Kamp uncorrected melting point with open capillaries, FT-IR by using Shemazdo (1800, KBr dis. in cm^{-1}), $^1\text{H-NMR}$ with Burker NMR, 400 MHz, C.H.N.S. analysis with LECO CHNS-923, and Mass with Agilent Technology (HP), MS Model 5973 Network mass Selective Detector with Electron Impact (EI) 70 eV, Analyzer: Quadrupole at Tehran University.

2.2 Compound [I]_a

A combination of P-acetamidophenol [a] (0.15 g, 0.01 mole) and ethyl α -chloroacetate (1.23 mL, 0.01 mole) in (15 mL) of dry-acetone refluxed for 6 hours in the presence of anhydrous K_2CO_3 (1.38 g, 0.01 mole). Then the finished mixture is cooled and placed on crushed ice. The white solid product was filtered and recrystallized from Et-OH after drying. yield 85%, m.p. 78°C [12], FT-IR (cm^{-1}): 3387 for sec. amide (ν -NH str.), 3002 (ν arom.-CH str.), 2939, 2866 (ν aliph. C-H str.), 1743 (ν C=O) carbonyl ester, 1681 (ν amide C=O), 1523 (ν C=C), 1315(ν C-N), 1242, and 1211(ν - C-O-C), 829 (ν P-substitution).

2.3 Compound [I]_b

Heating combination of 2-mercaptobenzoimidazol [b] (0.355 g, 0.001 mole), ethyl- α -Chloro-acetate (0.001 mole), and molten sodium-acetate (0.247 g, 0.003 mole) into absolute EtOH 5 mL for 4 hours After cooling the final mixture and immersing it in extremely cold water, we filter, dry, and recrystallize the resulting product in Et-OH. [13,14], yield 93%, m.p. 86-88°C, FTIR (cm^{-1}):3125 (ν NH), 3080 (ν arom.-CH), 2954, 2866 (ν aliph.CH), 1735 (ν C=O) ester, 1601 (ν C=N), 1504 (ν C=C); 1215 (ν C-O-), 759 (ν C-S-C).

2.4 General procedure for synthesis hydrazide derivatives [II]_{a,b}

Hydrazine hydrate 80% (8 mL) has been added to a solution of ester compounds [I]_{a,b} (0.03 mole) in ethanol at 12.5 mL and refluxed for 5–6 hours. After that, cool the mixture, off-white filter the product, dry it, and then recrystallize from EtOH [12-14].

2.4.1 Compound [II]_a

Molecular formula: $\text{C}_{10}\text{H}_{13}\text{N}_3\text{O}_3$, yield 89%, m.p. 155-157°C, White color, FT-IR (cm^{-1}): 3340-3190 (ν -NH₂,-NHSec.amide), 3055 (ν arom.-CH), 2924-2830 (ν aliph. C-H-), 1643 (ν C=O str.), 1570 (ν C=C), 1357 (ν -C-N-), 1230 (ν C-O-C).

2.4.2 Compound [II]_b

Molecular formula: $\text{C}_9\text{H}_{10}\text{N}_4\text{OS}$, yield 89%, m.p.78-80°C, colour off white, FT-IR (cm^{-1}): 3345-3184 (ν -NH-,NH₂ str.), 3020 (ν arom. CH str.), 2862,2820 (ν aliph.CH str.), 1651(ν C=O), 1616 (ν C=N str.), 1554 (ν C=C), 732 (ν S-C).

2.5 General procedure for preparation 1, 3, 4-Oxadiazol derivatives [III]_{a, b}

A combination of hydrazine type [II]_{a,b} (0.01 mole) and 4-aminobenzoic acid (0.01 mole, 1.37 g) in phosphorus oxychloride (5 mL) then refluxed for 6 hours. Once the reaction is complete, place the continent on the crushed ice. By using a solution of NaHCO_3 the mixture was neutralized. Et-OH washed, filtered, and recrystallized the yellow product [15–17].

2.5.1 Compound [III]_a

Molecular formula: C₁₇H₁₆N₄O₃, yield 75%, m.p. 258-260°C, yellow powder, FT-IR (cm⁻¹) 3383-3200 (ν -NH₂ str., -NH str.), 3070 (ν arom. C-H), 2839 (ν aliph.-C-H-), 1678 (ν C=O) sec. amide, 1647 (ν C=N), 1600 (ν C=C), 1323 (ν C-N), 1249 (ν C-O), 846 (ν p-substitution) [18].

2.5.2 Compound [III]_b

Molecular formula: C₁₆H₁₃N₅OS, yield 75%, m.p. 190–192 °C, greenish powder, FT-IR (cm⁻¹), 3340–3221 (ν -NH₂ str., -NH str.) The secondary amine has the following properties: 3020 (ν arom. CH str.), 2943-2831 (ν aliph. CH str.), 1645 (ν C=N), 1600 (ν C=C), 1257 (ν C-O), 837 (ν p-substitution), and 744 (ν C-S), according to [19].

2.6 General procedure for synthesizing Schiff bases [IV]_{a-f}

Schiff's bases for the prepared amines [III_a and III_b] were prepared by the general method (0.01 mole) from aldehydes (benzaldehyde, 5-bromo-2-hydroxybenzaldehyde, and 3-ethoxy-2-hydroxybenzaldehyde) and a few drops from glacial acetic acid in ethanol (15 mL), then added (0.01 mole) from synthesis amines (III_a and III_b), refluxed for 6 hours, then filtered the precipitate wash with methanol and recrystallization from ethanol.

2.6.1 Compound [IV]_a

Molecular formula: C₂₄H₂₀N₄O₃, yield 85%, light orange crystals, M.p. 165-167°C, FT-IR ν, cm⁻¹, 3232 (ν NH str.) Sec. amide, 3070 (ν arom. CH str.), 1685 (ν C=O str.) amide, 1654 (ν C=N) azomethine, 1564 (ν arom.C=C), 1215 (ν C-O str.).

2.6.2 Compound [IV]_b

Molecular formula: C₂₄H₁₉BrN₄O₄, yield 80%, brown product, m.p. 240-242°C, FT-IR ν, cm⁻¹, 3413-3170 (ν OH str.), 3332 (ν NH str.) Sec. amide, 3070 (ν arom. CH str.), 1670 (ν C=O str.) amide, 1650 (ν C=N str.) azomethine, 1573 (ν arom. C=C str.), 1226 (ν C-O str.), 702 (ν C-Br str.). Mass: *m/z*=507, 495, 452, 368, 291, 269, 171, 199, 120, 92, 57.

2.6.3 Compound [IV]_c

Molecular formula: C₂₆H₂₄N₄O₅, yield 85%, light orange crystals, m.p. 130-132°C, FT-IR ν, cm⁻¹, 3400-3332 (ν OH str.), 3217-3130 (ν NH str.) amide, 3066 (ν arom.CH str.), 2927, 2898 (ν aliph.CH str.), 1643 (ν C=N) azomethine, 1548 (ν arom. C=C), 1222 (ν C=O).

2.6.4 Compound [IV]_d

Molecular formula: C₂₃H₁₇N₅OS, yield 85%, orange product, m.p. 194-196°C, FT-IR ν, cm⁻¹, 3332 (ν NH str.) imidazole ring, 3055 (ν arom. CH str.), 1610(ν C=N) azomethine, 1600 (ν arom. C=C), 1068 (ν C=O), 744 (ν C-S).

2.6.5 Compound [IV]_e

Molecular formula: C₂₃H₁₆BrN₅O₂S, yield 85%, light brown product, m.p. 252-254°C, FT-IR ν, cm⁻¹, 3190 (ν OH str.), 3348 (ν NH str.) imidazole ring, 3051 (ν arom.CH str.), 2978 (ν aliph. CH str.), 1651 (ν C=N) azomethine, 1600 (ν arom.C=C str.), 1260 (ν C-O), 744 (ν C-S), 624 (ν C-Br). ¹H-NMR δ ppm: (N-H) at 10.44 (s,1H), (OH) at δ8.91 (s,1H), (CH=N) at 8.6 (s,1H), Ar-H at 8.22 -6.62 (m,11H arom.), (S-CH₂) at 4.63, 4.21 (s, 2H). C.H.N.S. Found %: C, 54.40; H 3.20; N 13.70; S 6.30. Calculated%: C, 54.55; H 3.18 ; N 13.83; S, 6.33. Mass: *m/z*= 468.

2.6.6 Compound [IV]_f

Molecular formula: C₂₅H₂₁N₅O₃S, yield 85%, orange product, m.p. 248-250°C, FT-IR ν, cm⁻¹, 3217 (ν OH str.), 3336 (ν NH str.) imidazole ring, 3062 (ν arom.CH), 1647 (ν C=N) azomethine, 1597 (ν arom. C=C), 1249 (ν C-O), 740 (ν C-S).

2.7 Synthesis of Thiazolidin-4-one derivatives [V]_{a-f}

The 4-Thiozolidinone derivatives were prepared according to the previously used method [20, 21].

2.7.1 Compound [V]_a

Molecular formula: C₂₆H₂₂N₄O₄S, yield 85%, off white powder, m.p. 267-269°C, FT-IR ν , cm⁻¹, 3332-3224 (ν NH str.) Sec. amide, 3055 (ν arom. CH str.), 2968 (ν aliph. CH str.), 1739 (ν C=O) thiazolidin-4 ring, 1670 (ν C=O) for amide, 1562 (ν arom. C=C str.), 1219 (ν C-O), 744 (ν C-S).

2.7.2 Compound [V]_b

Molecular formula: C₂₆H₂₁BrN₄O₅S, yield 79%, light yellow powder, m.p. 240-242°C, FT-IR ν , cm⁻¹, 3200 (ν OH str.), 3373 (ν NH str), Sec. amide, 3070 (ν arom. CH str.), 1672 (ν C=O) thiazolidin-4 ring, 1593 (ν arom. C=C str.), 1226 (ν C-O), 777 (ν C-S), 709 (ν C-Br). ¹H-NMR 400 MHz δ ppm: 10.20 (N-H, s, 1H), 7.69-6.54 (m, 11H arom.), 6.44-8.01 (s, 1H, OH), 5.52 (2H, S-CH₂), 5.08 (1H, N-CH-S), 3.67 (s, 2H, OCH₂), 2.15 (s, 3H, CH₃). C.H.N.S. Found %: C 53.60; H, 3.59; N, 9.60; S 5.50. Calculated %: C, 53.71; H 3.64; N 9.64; S, 5.51.

2.7.3 Compound [V]_c

Molecular formula: C₂₈H₂₆N₄O₆S, yield 85%, pale yellow, m.p. 260-262°C, FT-IR ν , cm⁻¹, 3411-3330 (ν OH str.), 3350 (ν NH str.) Sec. amide, 3059 (ν arom. CH str.), 2873 (ν aliph. C-H str.), 1740 (ν C=O str.) carbonyl ring, 1700 (ν C=O) amide, 1597 (ν arom. C=C str.), 1249 (ν C-O str.), 736 (ν C-S).

2.7.4 Compound 3-(4-(5-(((1H-Benzo[d]imidazol-2-yl)thio)Methyl)-1,3,4-Oxadiazol-2-yl)phenyl)-2-phenylthiazolidin-4-one [V]_d

Molecular formula: C₂₅H₁₉N₅O₂S₂, yield 85%, pale yellow, m.p. >310°C, FT-IR ν (cm⁻¹), 3344 (ν N-H str.) imidazole ring, 3062 (ν arom. C-H str.), 1720 (ν C=O) carbonyl-ring, 1640 (ν C=N str.) ring, 1597 (ν arom. C=C), 1273 (ν C-O), 744 (ν C-S).

2.7.5 Compound [V]_e

Molecular formula: C₂₅H₁₈BrN₅O₃S₂, yield 85%, light brown product. m.p. 280-282 °C, FT-IR ν , cm⁻¹, 3236 (ν OH str.), 3346 (ν NH str.) imidazole, 3095 (ν arom. CH str.), 1722 (ν C=O str.) ring, 1600 (ν arom. C=C str.), 1648 (ν C=N) ring, 1250 (ν C-O), 744 (ν C-S), 702 (ν C-Br str.). ¹H-NMR 400 MHz, δ ppm: 10.39 (s, 1H, N-H), 8.03 (s, 1H, OH), 8.05-6.45 (m, 11H arom.), 4.45 and 5.53 (s, 3H, (S-CH₂ and N-CH-S of ring), 3.73 (s, 2H, SCH₂). C.H.N.S. Found %: C 51.70; H, 3.10; N, 12; S 11.02. Calculated %: C 51.73; H, 3.13; N, 12.06; S 11.05.

2.7.6 Compound [V]_f

Molecular formula: C₂₇H₂₃N₅O₄S₂, yield 85%, light brown product, m.p. > 310°C, FT-IR ν , cm⁻¹, 3217 (ν OH str.), 3345 (ν NH str.) imidazole, 3062 (ν arom. CH str.), 1720 (ν C=O) ring, 1600 (ν arom. C=C str.), 1642 (ν C=N) oxadiazole ring, 1246 (ν C-O), 744 (ν C-S). ¹H NMR 400 MHz, DMSO δ ppm: 10.35 (s, 1H, NH), 8.03 (s, 1H, OH), 5.48, 5, 95 (1H, -NCHS-), 7.80-6.88 (m, 11H arom.), 3.64 (s, 2H, S-CH₂), 4.05 (2H, CH₂), 3.64-3.28 (5H, CH₃CH₂), 2.46 (3H, CH₃). C.H.N.S. Found %: C, 59.35; H, 4.20; N, 12.76; S 11.70. Calculated %: C, 59.43; H 4.25; N 12.84; S, 11.75.

2.8 General procedure for preparation of aldehydes [VI]_{a-c}

The aldehydes used in this reaction was prepared by references [22–25]. 4-methoxyphenyl 4-formyl benzoate VI a, off-white powder, m.p. 76-78 °C. 4-formylphenyl 4-butoxybenzoate VI b, off-white powder, m.p. 174-176 °C. 5'-formyl-2'-mydroxy-3'-methoxy-[1,1'-biphenyl]-4-yl)4-methoxybenzoate VI c, off-white powder, m.p. 118-120 °C.

2.9 General procedure Synthesis of alkene from thiazoldin-4-one derivatives [VII]_{a-f}

The compound [V]_{a-f} (0.01 mole) was mixed with (0.015 mole) from aldehydes [VI] in 1 mL of pyridine, then the mixture was put in reflux for 4 hours. After cooling, the reaction product solidifies in the reaction flask and forms a precipitate in crushed ice. The product was filtrated, washed with water, dried, and recrystallized with ethanol [14].

2.9.1 Compound [VII]_a

Molecular formula: C₄₄H₃₈N₄O₇S, Yield 75%, off-white powder, m.p. 84-86 °C, FT-IR ν , cm⁻¹, 3332 (ν NH str.) Sec. amide, 3070 (ν arom. CH str.), 1726 (ν C=O str.) ester, 1701 (ν C=O) amide, 1654 (ν C=N) ring, 1625 (ν C=C) alkene, 1602 (ν arom. C=C), 1209 (ν C-O), 745 (ν C-S). ¹H-NMR400MHZ, δ ppm: 10.03 (s,1H,NH), 8.68-7.11 (m, 21H arom.) and (s, 1H) C=CH, 5.30 (s, 1H) CH,4.11 (s,2H), 4.08 (t,2H)OCH₂, 2.46 (s,3H) CH₃C=O, 1.76 and 1.75 (m, 6H), 1.44 (s, 3H) CH₃. C.H.N.S. Found %: C, 59.65; H, 3.76; N, 6.72; S 3.77. Calculated %: C, 60.08; H 3.81; N 6.84; S 3.91.

2.9.2 Compound [VII]_b

Molecular formula: C₄₁H₃₁BrN₄O₈S, yield 73%, yellow powder, m.p. 86-88°C, FT-IR ν , cm⁻¹, 3180(ν OH str.), 3363 (ν NH str.) Sec. amide, 3070 (ν arom. CH str.), 1730 (ν C=O) ester, 1697 (ν C=O)amide,1640(ν C=N) 1631 (ν C=C str.)alkene, 1602 (ν arom. C=C), 1211 (ν C-O), 761(ν C-S), 649 (ν C-Br).¹H-NMR400MHZ, δ : 10.03 (s,1H,NH), 8.57 (s,1H) OH, 8.12- 7.14 (m, 20H arom.) and (s,1H) C=CH, 5.06 (s, 1H) CH, 3.88 (5H) OCH₂ and OCH₃, 2.13 (s, 3H) CH₃C=O. C.H.N.S. Found % : C, 60.05; H, 3.76; N, 6.75; S 3.65. Calculated %: C, 60.08; H,3.81;N 6.84; S 3.91.

2.9.3 Compound [VII]_c

Molecular formula: C₅₀H₄₂N₄O₁₁S, yield 85%, brown powder, m.p. 124-126°C, FT-IR ν , cm⁻¹, 3120 (ν OH str.), 3350 (ν NH str.) Sec. amide, 3070 (ν arom. CH str.), 1724(ν C=O)ester, 1691 (ν C=O) amide, 1630 (ν C=C) alkene, 1212 (ν C-O).¹H-NMR400MHZ, δ ppm: 9.99 (s,1H,NH), 8.07 (s,1H) OH and (s, 1H) C=CH, 8.06-7.10 (m, H arom.), 5.07 CH, 3.87-3.84 (s, 2H) OCH₂, OCH₃, 2.44(s, 3H) CH₃CO, 1.22(t, 3H) CH₃. C.H.N.S. Found % : C 66. 20; H,4.57; N, 6.15;S 3.44. Calculated %: C 66.21; H, 4.67; N, 6.18; S 3.54.

2.9.4 Compound [VII]_d

Molecular formula: C₄₃H₃₅N₅O₅S₂, yield 85%, yellow powder, m.p. 76-78°C, FT-IR ν , cm⁻¹, 3404 (ν NH str.) imidazole ring, 3062 (ν arom. CH str.), 1726 (ν C=O) ester, 1690 (ν C=O) amide,1629(ν C=C str.) alkene, 1652 (ν C=N) ring, 1602 (ν arom. C=C str.), 1390 (ν C-N str.), 1213 (ν C-O), 757 (ν C-S).¹H-NMR400MHZ, δ ppm: 10.0(s,1H,NH), 8.19-7.13(m, 21H arom.), 6.75-8.66 for (C=CH), 5.52 (s, 1H) CH, 5,62 (s, 2H) SCH₂,4.09 (2H. OCH₂), 1,23 (s, 2H) CH₂,0.85 (s, 3H) CH₃. C.H.N.S. Found %: C67.20; H, 4.45; N, 9.09; S 8.20. Calculated%: C 67.43; H 4.61; N, 9.14; S, 8.37.

2.9.5 Compound [VII]_e

Molecular formula: C₄₀H₂₈BrN₅O₆S₂, yield 85%, brown powder, m.p. 150-152°C, FT-IR ν , cm⁻¹, 3201 (ν OH str.), 3384(ν NH str.) imidazole ring, 3062 (ν arom. CH str.), 1730 (ν C=O) ester, 1695 (ν C=O str.) amide, 1629 (ν C=C)alkene, 1652 (ν C=N) ring, 1602 (ν arom. C=C str.), 1357 (ν C-N), 1213 (ν C-O), 761 (ν C-S), 688 (ν C-Br).¹H-NMR400MHZ, δ ppm: 10.0 (s,1H,NH), 8.58 (s,1H) OH, 7.378.09 (m, 19-H-arom.) and C=CH, 5.8 (s, 2H) SCH₂, 2.29 (d, 2H) CH₂, 1.84 CH₂CH₃. C.H.N.S. Found %: C 58.47; H 3.35; N 8.47; S 7.69. Calculated %: C 58.68; H 3.45; N 8.55; S 7.83.

2.9.6 Compound [VII]_f

Molecular formula: C₄₉H₃₉N₅O₉S₂, Yield 85%, pale yellow powder, m.p. 224-226°C, FT-IR ν , cm⁻¹, 3201 (ν OH str.), 3361 (ν NH str.) imidazole ring, 3070 (ν arom.CH str.), 1722 (ν C=O) ester, 1691 (ν C=O str.) amide, 1630 (ν C=C str.) alkene, 1654 (ν C=N)ring, 1604 (ν arom. C=C str.), 1382 (ν C-N), 1209 (ν C-O), 761 (ν C-S). ¹H-NMR400MHz δ ppm: 10.03 (s,1H,NH), 9.20 (s,1H) OH, 8.67-7.11 (m, H-arom.) and 7.21 (s, 1H) C=CH, 5.82 CH, 4.12 SCH₂ and OCH₂, 1.75, 1.72 and 1.41 (m, 3CH₂), 0.96(t, 3H), 4.29 (s, 3H) OCH₃. C.H.N.S. Found %: C 64.80;H, 4.25; N, 7.62; S 7. Calculated%: C 64.96; H, 4.34; N, 7.73; S 7.08.

2.10 The antibacterial assay

Using the plate-agar method and Mueller-Hinton culture medium, the biological activity of the prepared compounds was evaluated against two types of Gram-positive (*Enterococcus faecalis* and *Staphylococcus aureus*) bacteria and two types of Gram-negative (*E. coli* and *Pseudomonas aeruginosa*) bacteria.


2.11 Molecular modelling for synthesis alkenes

The structures of the derivatives were prepared using the Chem. Office.15 program and used the program MOE 2014 for a molecular modeling study of derivatives prepared with one of the Corona virus proteins (2W2G). The 3D structure for the studied protein was obtained from the Protein Database Bank (www.rcsb.org).

3. Results and Discussion

Starting with Paracetamol and 2-mercaptobenzimidazole, the ester was prepared for it Ia and Ib. Then the resulting esters were reacted via hydrazine hydrate (NH₂-NH₂) EtOH to produce hydrazides [II]a, [II]b, which were converted to 1,3,4-oxadiazoles [III]a and [III]b, then reacted with 4-aminobenzoic acid in the presence of a POCl₃. The later compounds condensed with aldehydes (Benz aldehyde, 3-ethoxybenzaldehyde, and 5-bromo-2-hydroxybenzaldehyde) led to the formation of Schiff bases compounds [IV]a-f. Thiazolidin-4-ones derivatives V a-f obtained via reacting Schiff compounds and 2-mercapto acetic acid in benzene under reflux. The final compounds [VII]a-f were synthesized via reflux of the resulting thiazolidine-4-ones derivatives [V]a-f with aldehydes (4-methoxyphenyl 4-formyl benzoate, 5'-formyl-2'-Hydroxy-3'-Methoxy-[1,1-Biphenyl]-4-yl)4-methoxy benzoate, and 4-formyl phenyl 4-butoxy benzoate) [VI]a-c in the presence of pyridine, the synthesis route of these reactions is shown in **Scheme 1**. Spectrophotometric methods confirmed new structure derivatives (FTIR, ¹H-NMR, Mass, and C.H.N.S analysis). FTIR spectrum for [I] a and [I] b show the bands appearance at 1743 cm⁻¹, and 1735 cm⁻¹ attributed to carbonyl ester str. str. In hydrazide compounds, II appearance two bands between (1651-1643) and the band in (3309-3194 cm⁻¹) to the ν C=O and ν (-NH₂, NH) for IIa,b besides to bands at ν (3340-3220) cm⁻¹ which indicate the ν (-NH₂) group. Schiff bases IVa-f were identified via the azomethine group absorption band at 1604-1610 cm⁻¹. The ¹H-NMR spectrum for IVe show single at 10.22 δ attributed to NH imidazole ring proton, a singlet at 8.91 δ due to OH proton, singlet at 8.61 δ due to azomethine group proton C=NH, multiply singlets at 8.22-6.62 δ for 11 aromatic protons, and singlet at 4.63, 4.21 δ due to S-CH₂ protons. For 4-thiazolidine derivatives Va-f, their formation can be confirmed by FT-IR, the disappearance of the azomethine adsorption band, and the appearance of the carbonyl-group ν C=O for a five-membered ring of thiazolidine-4-one at 1715-1712 cm⁻¹. The ¹H-NMR spectrum for Vb shows single at δ 10.20 δ due to N-H amide proton in paracetamol, multiply signals at 6.4-8.01 δ attributed to 12 aromatic protons +OH proton, singlet at 5.04 δ for O-CH₂ protons, singlet at δ 5.52 ppm for ν

NCH-S in the ring of the thiazolidine-4-one ring, and single at δ 3.67 ppm due to CH_2 methyl protons in ring and finally three protons of CH_3 appeared at δ 2.19 ppm.



Scheme 1. Synthetic route for the new thiazolidin-4-ones derivatives.

While $^1\text{H-NMR}$ for Ve displays single at δ 10.39 ppm due to NH proton imidazole ring, multiply singles at 8.05-6.45 ppm for 11 aromatic protons and OH proton, at δ 4.45, 5.53 ppm singles due to S- CH_2 and NCHS of ring proton, besides to a singles at 3.37 for CH_2 proton in the ring, single. The $^1\text{H-NMR}$ for Vf show single at δ 10.35 ppm imidazole ring proton, multiply singles at δ 8.6-6.46 ppm due to 11 aromatic protons and OH proton, also two singles at δ 5.48, 5.95 ppm for S CH_2 proton and NCHS proton, and single at δ 4.05 ppm due to O-CH 2 proton, where single at δ 3.64 ppm refer to CH_2 protons in the ring. The final compounds VII a-f were characterized by FT-IR, which showed sharp bands for C=O (ester) derivatives in the range 1724-1730 cm^{-1} , alkene band C=C in the range 1631-1625 cm^{-1} , and suitable band around 1209-1211 cm^{-1} for C-O ester linkage. The $^1\text{HNMR}$ spectra for derivatives VII a-f are as below; derivative VIIa single at δ 10.03 ppm for NH proton, multiply singles at δ 7.0-8.05 ppm refers to the 21 aromatic protons, which interfere with the alkene proton signal C=CH, single at δ 5.27 ppm due to CH ring proton, single at δ 4.11 ppm attributed to OCH_2 proton and OC_2H_5 protons, two singles at δ (1.43 and 1.71) ppm due to two 2CH_2 protons and COCH_3 protons, single at δ 0.94 ppm for CH_2CH_3 protons. VII b has single at δ 10.03 ppm for NH proton, single at δ 8.57 ppm for OH proton, multiply signals at δ 8.12-7.14 resulting from the overlapping signals of the 18 aromatic protons and the alkene proton C=CH, single at δ 5.06 ppm due to CH ring proton, two signals at δ 3.88, and 3.69 ppm for OCH_2 and OCH_3 protons respectively, finally singlet at δ 2.13 ppm single due to $\text{CH}_3\text{C=O}$. VII d has single at δ 10.0 due to NH proton, overlapping signals of 19 aromatic protons with that of

alkene C=CH at δ 7.37-8.09 ppm, single at δ 5.8 ppm for SCH₂, also singlet at 3.82 ppm due to OCH₃ protons. VIIe has single at 10.0 ppm due to NH proton, at 8.58 ppm single due to OH proton, multiply singlets at δ 8.09-7.12 ppm for aromatic protons that interact with alkene proton C=CH, single at δ 5.8 ppm for SCH₂ protons, single at δ 2.29 due to CH₂ protons, single at δ 1.84 ppm for CH₂CH₃ protons.

3.1 Antibacterial activity

Using the plate-agar method, the newly synthesized derivatives were investigated for their biological activity against four different species of bacteria, including two gram-positive (*Enterococcus faecalis* and *Staphylococcus aureus*) and two gram-negative (*E. coli* and *Pseudomonas aeruginosa*) [26-28]. Four compounds of the derivatives containing the 4-thiazolidine rings [V]b, [V]c, [V]e, and [V]f were tested and compared with four of the alkenes [VII] b, [VII]c, [VII] e, and [VII]f prepared from them. The results showed that all the compounds under test had no biological activity against bacteria, *Pseudomonas aeruginosa*, and *E. coli*, whereas, compounds [V]b, and [V]c had moderate activity towards *Staphylococcus*, while the rest of the compounds under test had no efficacy against it. **Figure 1** shows the results diagram. The compounds under test were characterized by having moderate to somewhat high activity against *Enterococcus faecalis*, except for two compounds Ve, and V f that had weak effectiveness. The results of the derived alkenes [VII] b, [VII] c, [VII]e, and [VII]f were significantly higher than the compounds prepared from them [V] b, [V]c, [V]e, and [V]f. **Table 1** shows results in mm for zone inhibition and **Figure 2** displays the results on petri dishes.




Figure 1. The results diagram of antibacterial activity against synthesis derivatives (Vb, Vc, Ve, Vf, VIIb, VIIc, VIIe, and VIIf).




Figure 2. The Bacterial culture dishes. A: results of V_b , V_c , V_e , and V_f) against *staphylo*. B: results of V_b , V_c , V_e , and V_f) against *Enterococcus faecalis* . C: results of (VII_b , VII_c , VII_e , and VII_f) against *Enterococcus faecalis*.

3.2 Molecular docking study

I was studying the molecular modeling of the compounds prepared [VII]a-f with one of the Coronavirus proteins 2W2G (human SARA coronavirus unique) [29-32]. Molecular modeling was studied for the compounds with the large pocket, which was isolated from the studied protein (2W2G), where the binding energy was within the range of -8.08 kcal/mol, -6.78 kcal/mol; **Table 2** shows score docking results. [VII]a -7.65 kcal/mol as dock score with interaction by H-bond at LYS463 and π -H interaction at ASN418 and LYS491. [VII] b with - 6.78 as dock score conceded as the lowest with ASN418 by π -H interaction. [VII]c has the highest dock score with -8.08 kcal/mol., H-bond at LYS463, and π - H interaction with ASN597 and SER598. [VII]f has a -7.07 kcal/mol. Dock score with SER626, MET428, ARG628, and GLY491 with two H-bond and π -interaction. **Table 1** shows the modeling values and interactions with the studied protein. **Figure 3** shows some compounds with the studied protein in two dimensions.

Table 1. The dock score and interaction for synthesis compounds.

Com.	Dock-Score Kcal/mol.	Interaction residues
VII_a	-7.65	LYS463, ASN418, LYS463
VII_b	-6.78	ASN418
VII_c	-8.08	LYS463, ASN597, SER598
VII_f	-7.07	SER626, MET428, ARG628, GLY491




Figure .3. The 2D interaction and protein target surface for VII_a, and, VII_c,

4. Conclusion

In this study, new compounds derived from thiazolidine-4-ones were successfully prepared and identified by spectrophotometric methods. In their bacterial activity assay, where it was found that some of these compounds have high effectiveness against the studied bacteria, while others do not have any effectiveness, the results of the derived alkenes (VII_b, VII_c, VII_e, and VII_f) were significantly higher than the compounds prepared from them (V_b, V_c, V_e, and V_f). *Enterococcus faecalis* provided the best results. Some of the prepared compounds (VII_a, VII_b, VII_c, and VII_f) had good binding when doing molecular modeling against one of the SARS human coronavirus proteins where the binding energy was within the range of -8.08 kcal/mole to 6.78 kcal/mole.

Acknowledgment

The authors thank the Department of Chemistry, College of Education for Pure Science (Ibn Al-Haitham), University of Baghdad for research approval.

Conflict of Interest

The authors declare that they have no conflicts of interest.

Funding

No founding.

Ethical Clearance

This work has been approved by the Scientific Committee at the University of Baghdad/ College of Education for Pure Science (Ibn Al-Haitham).

References

1. Dhadda, S.; Sharma, S.; Jakar, P.; Sharma, H. Contemporary Progress in the Green Synthesis of Spiro-Thiazolidines and their Medicinal Significance: A Review. *The Royal Society of Chemistry Advances* **2023**, *13*(6), 3723-3742. <https://pubs.rsc.org/en/content/articlepdf/2023/ra/d2ra07474e>.
2. Irfan, A.; Batool, F.; Andleeb, S.; Naqvi, Z.; Islam, A.; Osman, S.M.; Nocentini, A.; Alissa, S.A.; Supuran, T. C. Benzothiazole Derivatives as Anticancer Agents. *Journal of Enzyme Inhibition and Medicinal Chemistry* **2020**, *35*(1), 265-279. <https://doi.org/10.1080/14756366.2019.1698036>.
3. Kumara, A.S.; Kumara, R.A.; Reddy, E.P.; Satyanarayana, V.; Kashannab, J.; Reddy, B.J.M.; Reddy, B.V.S.; Yadava, J.S. Synthesis of Novel 2-Thioxothiazolidin-4-one and Thiazolidine-2,4-dione Derivatives as Potential Anticancer Agents. *Natural Product Communications* **2018**, *13*(5), 589-559. <https://doi.org/10.1177/1934578X1801300518>.
4. Sankar, P.S.; Divya, K.; Padmaja, A.; Padmavathi, V. Synthesis and Antimicrobial Activity of Azetidione and Thiazolidinone Derivatives from Azolyindolyl Schiff's Bases. *Journal of Medicinal Chemistry* **2017**, *7*(11), 340-347. <https://doi.org/10.4172/2161-0444.1000478>.
5. Muhammad, A.; Raza, M.A.; Farwa, U. Synthesis, Characterization, Docking and *In-Vitro* evaluation of newly Synthesized Thiazolidinones. *Biologia (Lahore)* **2021**, *67*(II), 85-91. <https://www.researchgate.net/publication/359699959>.
6. Muhammad, A.; Sumra, M.A.; Javed, S.H.; Saqib, K.; Maurin, Z.; J.K. Synthesis, Characterization and Molecular Modeling of Amino Derived Thiazolidinones as Esterase and Glucosidase Inhibitors. *Journal of Molecular Structure* **2020**, *1219*, 128609. <https://doi.org/10.1016/j.molstruc.2020.128609>.
7. Tanuja; Singh, H. Design, Synthesis, Antimicrobial and Anticancer Evaluation of Thiazole Clubbed with 4-Thiazolidinone Derivatives. *Journal of Pharmaceutical Negative Results* **2022**, *13*(9), 3400-3408. <https://www.pnrjournal.com/index.php/home/article/view/4103/13087>.
8. Kryshchshyn-Dylevych, A.; Senkiv, J.; Roman, O.; Gzella, A.; Bielawski, K.; Bielawska, A.; Lesyk, R. Synthesis and Anticancer Activity Evaluation of 5-[2-Chloro-3-(4-nitrophenyl)-2-propenylidene]-4-thiazolidinones. *Molecules* **2021**, *26*(10), 3057. <https://doi.org/10.3390/molecules26103057>.
9. Chintakunta, R.; Subbareddy, G.V. Synthesis Docking Studies, Characterization and Anti-Tubercular Activity of Ofloxacin Containing Thiazolidinone Derivatives. *Journal of Young Pharmacists* **2022**, *14*(1), 77-81. <https://doi.org/10.5530/jyp.2022.14.15>.
10. Kassem, A.F.; Nassar, I.F.; Abdel-Aal, M.T.; Awad, H.M.; El-Sayed, W.A. Synthesis and Anticancer Activity of New ((Furan-2-yl)-1,3,4- Thiadiazolyl)-1,3,4-Oxadiazole Acyclic Sugar Derivatives. *Chemical and Pharmaceutical Bulletin* **2019**, *67*(8), 888-895. <https://doi.org/10.1248/cpb.c19-00280>.
11. Kumar, B. N.; Prasanna; Mohana, K. N.; Mallesha, L. Synthesis of *N*-[5-Aryl-1,3,4-oxadiazole-2-yl]methyl]-4-Methoxyaniline Derivatives and their Anticonvulsant Activity. *Journal of Chemistry* **2013**, *121029*, 1-7. <https://doi.org/10.1155/2013/121029>.
12. Gupta, V.; Pandurangan, A. Synthesis and Antimicrobial Activity of Some New 5-Oxo-Imidazolidine Derivatives. *American Journal of Advanced Drug Delivery* **2013**, *1*(4), 413-421. www.ajadd.co.uk.
13. Yadav, S.; Narasimhan, B.; Lim, S.M.; Ramasamy, K.; Vasudevan, M.; Adnan, S.; Shah, A.; Selvaraj, M. Synthesis, Characterization, Biological Evaluation and Molecular Docking Studies of 2-(1H-Benzo[D]Imidazol-2-Ylthio)-*N*-(Substituted 4-Oxothiazolidin-3-Yl) Acetamides. *Chemistry Central Journal* **2017**, *11*, 137. <https://doi.org/10.1186/s13065-017-0361-6>.

14. Tomma, J.H.; Al-Obaidi, O.B.; Al-Dujaili, A.H. A New Thiazolidinone and Triazole Derivatives: Synthesis, Characterization and Liquid Crystalline Properties. *Journal of Molecular Structure* **2022**, 1270-133817. <https://doi.org/10.1016/j.molstruc.2022.133817>.
15. Tomma, J.H.; Hussein, D.H.; Jamel, N.J. Synthesis and Characterization of Some New Quinoline-2-one, Schiff bases, Pyrazole and Pyrazoline Compounds Derived from Hydrazone Containing Isoxazoline or Pyrimidine Cycles. *Iraqi Journal of Science* **2016**, 57(2C), 1316-1332. <https://www.iasj.net/iasj/issue/7262>.
16. Tomma, J.H.; Khazaal, M.S.; Baker, R.K. Synthesis, Characterization and Antibacterial Activity of New Chalcones Derived from New Aldehyde; 4-[5-(4-Tolyl)-1,3,4-Thiadiazole-2-yl]Benzaldehyde. *Ibn Al-Haitham Journal for Pure and Applied Sciences* **2017**, 30(3), 68-76. <https://jih.uobaghdad.edu.iq/index.php/j/article/view/1603/1272>.
17. Hamdan, I.A.; Tomma, J.H. Synthesis and Study of the Biological Activity of Some New 1,3,4-Oxadiazoles Derived from Carboxylic Acid Compounds. *Iraqi Journal of Science* **2024**, 65(4), 1800-1812. <https://doi.org/10.24996/ijs.2024.65.4.2>.
18. Illango, A.K.; Valentina, P.; Umarani, N.; Kumar, T. Synthesis and Characterization of 2,5-Disubstituted 1,3,4-Oxadiazoles as Potential Anti-Inflammatory Agents. *Journal of Young Pharmacists* **2009**, 1(1), 72-76. <https://dx.doi.org/10.4103/0975-1483.51882>.
19. Chavan, P.S.; Nagarale, S.N.; Patil, M.V. Synthesis, Spectral Characterization and Antimicrobial Studies of New Hybrid Heterocyclic Compounds Bearing 1H-benzimidazol-2-yl Thiomethyl Motif. *Indian Journal of Pharmaceutical Sciences* **2017**, 79(3), 385-394. <https://doi.org/10.4172/pharmaceutical-sciences.1000241>.
20. Tandel, H.T. Synthesis and Antibacterial Activity of Coumarin Containing 4-Thiazolidinone Derivatives. *Journal of Research and Analytical Reviews* **2020**, 7(1), 239-251. www.ijrar.org.
21. Alheety, K.A.; Jamell, N.M.; Tomma, J.H. Synthesis and Biological Activity of Some New Thiazolidinone Derivatives. *Systemic Reviews in Pharmacy* **2020**, 11(3), 490-494. <https://doi.org/10.5530/srp.2020.3.62>.
22. Hassan, H.A.; Alheety, K.A.; Hassan, D.F.; Tomma, J.H. Synthesis and Identification of Novel 2-Thioxoimidazolidin-4-One Derivatives Containing Azo and Ester Groups. *International Journal of Pharmaceutical Research* **2019**, 11(3), 203-209. <https://doi.org/10.31838/ijpr/2019.11.03.033>.
23. Tomma, J.H. Synthesis and Study the Mesomorphic Behaviour of Some New 1,3,4-Thiadiazoline Derivatives. *Liquid Crystals* **2023**, 6, 998-1006. <https://doi.org/10.1080/02678292.2023.2190169>.
24. Jamel, N.M.; Baker, R.K.; Tomma, J.H. Synthesis, Characterization and Investigation the Antibacterial Activity of New Heterocyclic Compounds Derived from 4-(4-Methoxy Benzoyloxy) Benzaldehydethiosemicarbazone. *Ibn Al-Haitham Journal for Pure and Applied Sciences* **2017**, 30(1), 155-168. <https://jih.uobaghdad.edu.iq/index.php/j/article/view/1068/916>.
25. Tomma, J.H.; Al-Dujaili, H.A. Mesomorphic Behaviour of Some New Schiff Base Esters Containing 1,3,4-C₂H₂N₂O Unit. *Iraqi Journal Science* **2002**, 43(1), 35-57. <https://doi.org/10.1088/1757-899X/1145/1/012174>.
26. Tomma, J.H.; Abbas, S.F.; Al-Dujaili, A.H., New Quinolin-2-one, Indazole, and Benzisoxazole Derivatives Derived from Chalcones: Synthesis, Characterization, and Biological Activity. *Russian Journal of Organic Chemistry* **2023**, 59(6), 1027-1032. <https://doi.org/10.1134/S107042802306009X>.
27. Al-Majidi, M.H.S.; Ibrahim, H.A.R.; AL-issa, Y.A.H. Synthesis and Identification of Some New Derivatives of ([Benzyl Thio) Benzimidazole-N-(Methylene-5-Yl)]-4,5-Di Substituted 1,2,4-Triazole and Evaluation of their Activity as Antimicrobial and Anti-Inflammatory Agents. *Iraqi Journal of Science* **2021**, 62(4), 1054-1065. <https://doi.org/10.24996/ijs.2021.62.4.2>.
28. Abd-AL Hameed, W.M.; Tomma, J.H.; Baker, R.K. Synthesis and Study the Biological Activity of New Heterocyclic Compounds Derived from Hydrazone Derivatives. *Indian Journal of Forensic Medicine and Toxicology* **2020**, 14(4), 1881-1887. <https://doi.org/10.37506/ijfmt.v14i4.11819>.

29. Desai, C.N.; Jadeja, K.A.; Jadeja, D.J.; Khedkar, M.V.; Prakash, C.J. Design, Synthesis, Antimicrobial Evaluation, and Molecular Docking Study of Some 4-Thiazolidinone Derivatives Containing Pyridine and Quinazoline Moiety. *Synthetic Communications* **2020**, *51*(6), 1-12. <https://doi.org/10.1080/00397911.2020.1861302>.
30. Lei, J.; Ma-Lauer, Y.; Han, Y.; Thoms, M.; Buschauer, R.; Jores, J.; Thiel, V.; Beckmann, R.; Deng, W.; Leonhardt, H.; Hilgenfeld, R.; Von Brunn, A. The SARS-Unique Domain (SUD) of SARS-Cov and SARS-Cov-2 Interacts with Human Paip1 to Enhance Viral RNA Translation. *The EMBO Journal* **2021**, *40*(11), e102277. <https://doi.org/10.15252/emj.2019102277>.
31. Staup, A.J.; De Silva, I.U.; Catt, J.T.; Tan, X.; Hammond, R.G.; Johnson, M.A. Structure of the SARS-Unique Domain C from the Bat Coronavirus HKU4. *Natural Product Communications* **2019**, *14*(5), 1934578X19849202. <https://doi.org/10.1177%2F1934578X19849202>.
32. Qin, B.; Li, Z.; Tang, K.; Wang, T.; Xie, Y.; Aumonier, S.; Meitian, W.M.; Yuan, S.; Cui, S. Identification of the SARS-Unique Domain of SARS-Cov-2 as an Antiviral Target. *Natural Communications* **2023**, *14*(1), 3999. <https://doi.org/10.1038/s41467-023-39709-6>.